Bispecific T cell engagers kill resistant cells during KRAS-G12C blockade therapy

Xinxin Song; Zhuan Zhou; Rui Kang; Daolin Tang

doi:10.1080/2162402X.2022.2141978

OncoImmunology (Dec 2022)

Bispecific T cell engagers kill resistant cells during KRAS-G12C blockade therapy

Xinxin Song,
Zhuan Zhou,
Rui Kang,
Daolin Tang

Affiliations

Xinxin Song: Department of Surgery, UT Southwestern Medical Center, Dallas, Texas, USA
Zhuan Zhou: Department of Surgery, UT Southwestern Medical Center, Dallas, Texas, USA
Rui Kang: Department of Surgery, UT Southwestern Medical Center, Dallas, Texas, USA
Daolin Tang: Department of Surgery, UT Southwestern Medical Center, Dallas, Texas, USA

DOI: https://doi.org/10.1080/2162402X.2022.2141978
Journal volume & issue: Vol. 11, no. 1

Abstract

Read online

The covalent KRAS-G12C inhibitors (G12Ci) are rapidly changing the treatment landscape for advanced non-small cell lung cancer, but drug resistance remains a clinical challenge. Two recent studies have developed bispecific T cell engagers that form a link between T cells and tumor cells to selectively eliminate G12Ci-resistant cells.

Published in OncoImmunology

ISSN: 2162-402X (Online)
Publisher: Taylor & Francis Group
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy; Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.tandfonline.com/journals/koni

About the journal

Abstract

Keywords